Subscribe to Newsletter
Business & Regulation Small Molecules, Business Practice


  • Catalent has completed its purchase of a Bristol-Myer-Squibb site in Anangi, Italy. The site, which has capabilities to support product launches for oral solids, as well as the production of primary and secondary packaging solutions will help reduce “time-to-market, simplify tech transfers, and minimize program risk” across Catalent’s European network. Catalent will continue to manufacture the existing Bristol-Myers Squibb product portfolio currently produced at the site.
  • Alcami has announced the sale of its preclinical and early stage API facility in Weert, the Netherlands, to MercachemSyncom. The company has been taking a number of steps recently to improve productivity across its sites. Despite selling the Weert-based site, the company says it will retain its European sales and business development team.
  • Sanofi’s Chief Executive Officer, Paul Hudson, announced plans to reduce the company’s reliance on CMOs to improve cost savings. The company hopes to find €2 billion dollars by 2022 and predicts that cutting down on CMO use will contribute €500 million (the rest is expected to come from reduced spending on deprioritized businesses and general procurement savings). The company also explained that it would be letting go of its “low-selling” product families, leaving them with 100 by 2025.
Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Maryam Mahdi

Deputy Editor

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine